167 related articles for article (PubMed ID: 3499211)
1. Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia. Potential selective effect in T-cell leukemia.
Lauer SJ; Pinkel D; Buchanan GR; Sartain P; Cornet JM; Krance R; Borella LD; Casper JT; Kun LE; Hoffman RG
Cancer; 1987 Nov; 60(10):2366-71. PubMed ID: 3499211
[TBL] [Abstract][Full Text] [Related]
2. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
[TBL] [Abstract][Full Text] [Related]
3. Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L.
Dahl GV; Rivera GK; Look AT; Hustu HO; Kalwinsky DK; Abromowitch M; Mirro J; Ochs J; Murphy SB; Dodge RK
J Clin Oncol; 1987 Jul; 5(7):1015-21. PubMed ID: 3474355
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.
Schaison G; Leverger G; Bancillon A; Marty M; Olive D; Cornu G; Griscelli C; Lemerle S; Harousseau JL; Bonnet M
Haematol Blood Transfus; 1987; 30():461-5. PubMed ID: 3305213
[No Abstract] [Full Text] [Related]
5. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
[TBL] [Abstract][Full Text] [Related]
6. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study.
van Eys J; Berry D; Crist W; Doering E; Fernbach D; Pullen J; Shuster J; Wharam M
Cancer; 1989 Jan; 63(1):23-9. PubMed ID: 2910421
[TBL] [Abstract][Full Text] [Related]
7. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study.
Sullivan MP; Chen T; Dyment PG; Hvizdala E; Steuber CP
Blood; 1982 Oct; 60(4):948-58. PubMed ID: 6956376
[TBL] [Abstract][Full Text] [Related]
8. [The Munich study on the treatment of acute lymphoblastic leukemia in childhood (ALL 77-02)].
Graubner UB; Haas RJ; Janka G; Gaedicke G; Kohne E; Rieber EP
Klin Padiatr; 1985; 197(3):207-14. PubMed ID: 3892149
[TBL] [Abstract][Full Text] [Related]
9. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
10. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
[TBL] [Abstract][Full Text] [Related]
12. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
13. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
[TBL] [Abstract][Full Text] [Related]
14. [Acute lymphoblastic leukemia in children. Long survivals obtained with protocols C2-72 and D-74 (1972-1977)].
Ortega JJ; Javier G; Montagut JM; Torán N
An Esp Pediatr; 1986 Feb; 24(2):87-97. PubMed ID: 3516041
[TBL] [Abstract][Full Text] [Related]
15. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
[TBL] [Abstract][Full Text] [Related]
16. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A
J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717
[TBL] [Abstract][Full Text] [Related]
17. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
[TBL] [Abstract][Full Text] [Related]
18. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
19. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL
J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525
[TBL] [Abstract][Full Text] [Related]
20. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
